Epic Research

Tuesday, February 5, 2013

Epic Update : Biocon

Have arrived at baseline valuation for listing Syngene
Would like to list Syngene when macro conditions benign
In advanced talks for outlicensing Human insulin
Planning partnership route to take Itolizumab Global
Biocon’s Itolizumab is used for treating Psoriasis.

Get Free MCX TipsStock TipsForex Tips & NCDEX Tips,Commodity TipsShare Tipscommodity tips free trialnifty free tipscommodity trading tipsshares tipsShare Market TipsStock Market Tipsfree stock tips on mobileStock trading tipsIntraday Tips.

No comments:

Post a Comment